Description

Surerab-L is a medicine that contains the combination of Rabeprazole and Levosulpride in sustained-release tablet form. Rabeprazole is a proton pump inhibitor that reduces the production of stomach acid, while Levosulpride is a selective dopamine D2 receptor antagonist with prokinetic properties. This combination is primarily prescribed to treat various gastrointestinal disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, and dyspepsia. It helps alleviate symptoms such as heartburn, acid regurgitation, stomach pain, and indigestion. Rabeprazole in Surerab-L inhibits the acid secretion in the stomach, providing relief from acidity-related discomfort. Levosulpride acts by increasing the motility of the gastrointestinal tract, aiding digestion, and reducing symptoms like bloating and abdominal discomfort. It is crucial to follow the recommended dosage and duration of treatment to achieve optimal results and minimize the risk of side effects.

Additional information